Under and misuse of hormone therapy decreasing, but still high
(University of Chicago Medical Center) A nationwide cancer registry of almost one million patients treated for hormone-sensitive breast cancer shows that one out of six women who should have received post-surgical treatment known as adjuvant endocrine therapy did not get this recommended component of care, which can reduce the odds of recurrence. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 2, 2017 Category: Cancer & Oncology Source Type: news
FALCON Breast Cancer Trial: Who's Naive Here? FALCON Breast Cancer Trial: Who's Naive Here?
In the FALCON trial, fulvestrant improved PFS in ER+ metastatic breast cancer patients who were endocrine-therapy naive, but the trial failed to answer key clinical questions, says Dr Lidia Schapira.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 6, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
This research has been highlighted as a practice changing update by DynaMed Plus. It concludes that Fulvestrant has superior efficacy and is a preferred treatment option for patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not received previous endocrine therapy compared with a third-generation aromatase inhibitor, a standard of care for first-line treatment of these patients (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 4, 2017 Category: Consumer Health News Source Type: news
Stretching PFS in ER-Positive Metastatic Breast Cancer Stretching PFS in ER-Positive Metastatic Breast Cancer
In metastatic breast cancer, the current 14-16 months of PFS with endocrine therapy can be stretched to more than 20 months in the first-line setting, as explained in a plenary session at SABCS.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 21, 2016 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news
Endocrine Therapy in Breast Cancer: Best Bet on Duration Endocrine Therapy in Breast Cancer: Best Bet on Duration
Dr Harold Burstein reviews the latest data on duration of adjuvant endocrine therapy in metastatic breast cancer, and provides much-needed recommendations on how to approach the topic with patients.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 19, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
One in Five Breast Cancer Patients Nonadherent to Endocrine Therapy
A study found that about 20% of women with breast cancer did not complete their prescribed endocrine therapy. (Source: CancerNetwork)
Source: CancerNetwork - December 16, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Breast Cancer News Source Type: news
Breast cancer patients fail to complete tamoxifen therapy
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, such as tamoxifen, according to researchers. (Source: Nursing Times)
Source: Nursing Times - December 14, 2016 Category: Nursing Source Type: news
Almost 20 percent of breast cancer patients fail to complete prescribed endocrine therapy
(European Society for Medical Oncology) Around 20 percent of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore. The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy were less likely to adhere to their medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 14, 2016 Category: Cancer & Oncology Source Type: news
B-52 Study: Estrogen Deprivation Bombs for Breast Ca (CME/CE)
(MedPage Today) -- Endocrine therapy fails to improve pre-surgery complete response rates (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - December 9, 2016 Category: Journals (General) Source Type: news
Precision Endocrine Therapy Possible in Breast Cancer Patients?
In a potential step toward precision endocrine therapy, a new study found that certain single nucleotide polymorphisms within CSMD1 are associated with changes in estrogen levels in postmenopausal breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Conferences/SABCS 2016 Source Type: news
Ribociclib Increases Survival in HR+ Advanced Breast Cancer, But … Ribociclib Increases Survival in HR+ Advanced Breast Cancer, But …
Ribociclib + letrozole improves PFS in HR+ breast cancer, but Dr Lidia Schapira says more data are needed to identify which patients should receive endocrine therapy alone or combination therapy.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 9, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news
PI3K Inhibitor Delays Progression in Advanced HR-Positive Breast Cancer
Treatment with buparlisib in combination with endocrine therapy significantly improved PFS compared with placebo in patients with HR-positive advanced breast cancer that had progressed after treatment with everolimus plus exemestane. (Source: CancerNetwork)
Source: CancerNetwork - December 8, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Conferences/SABCS 2016 Source Type: news
Extending Adjuvant Endocrine Therapy: 3 Trials, Few Answers Extending Adjuvant Endocrine Therapy: 3 Trials, Few Answers
NSABP B-42, IDEAL and DATA trials dig down to small details.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 7, 2016 Category: Radiology Tags: Hematology-Oncology News Source Type: news
Hormone therapy better than chemo before breast cancer surgery, study says
Doug G. WareBOSTON, Nov. 9 (UPI) -- Pre-surgery endocrine therapy for women with breast cancer might be every bit as good as chemotherapy, or even better, prominent new research said Wednesday. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 9, 2016 Category: Consumer Health News Source Type: news
Presurgical endocrine therapy less toxic than chemotherapy for ER-positive breast cancer
(Massachusetts General Hospital) Neoadjuvant endocrine therapy -- designed to reduce the size of breast tumors before surgical removal -- appears to be as effective as neoadjuvant chemotherapy for patients with localized, estrogen-receptor (ER)-positive breast cancer with considerably fewer side effects. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 9, 2016 Category: Cancer & Oncology Source Type: news
